Fuller & Thaler Asset Management, Inc. Verastem, Inc. Transaction History

Fuller & Thaler Asset Management, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$2.79 - $4.09 $1.04 Million - $1.52 Million	-371,077 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.23 - $7.01 $373,388 - $810,356	115,600 Added 45.25%	371,077 $1.25 Million
Q3 2018 Nov 13, 2018	BUY	$6.86 - $9.97 $1.75 Million - $2.55 Million	255,477 New	255,477 $1.85 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.29B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Fuller & Thaler Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Fuller & Thaler Asset Management, Inc. with notifications on news.